Elicio Therapeutics publishes research on AMP-DNA adjuvant technology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
June 1, 2026 8:00 AM EDTPreclinical data demonstrate robust T cell activation, durable immune memory, and lymph node-targeted mechanism supporting next-generation immunotherapies
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, Elicio or the Company), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of a peer-reviewed manuscript in Science Advances, published by the American Association for the Advancement of Science, describing a series of novel AMP-DNA adjuvant candidates built from the lymph node-targeting Amphiphile (AMP) platform technology. Â
The manuscript, titled Lymph node targeted DNA engages TBK1/IFN-I driven innate... More
